Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax plus DA-EPOCH-R for double/triple-hit high-grade B-cell lymphoma
ChiCTR2100048811Phase 4Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of venetoclax in large-cell lymphoma, sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Complete response rate. Started Jul 2021; status: recruiting.
02
Drugs
venetoclax
03
Conditions
large-cell lymphoma
Beyond the preview
Go deeper on ChiCTR2100048811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048811.